CALGARY, ALBERTA--(Marketwire - July 25, 2007) - Resverlogix Corp. ("Resverlogix") (TSX:RVX) is pleased to announce today important data from a non-human primate study on the clinical lead compound, RVX-208. Data highlights from the study in adult African green monkeys illustrate that RVX-208 elevates both ApoA-I and HDL-c in a dose-dependent manner. When RVX-208 was administered over 28-day and 42-day treatment regimens, ApoA-I levels were increased up to 52% and HDL cholesterol levels increased up to 75%. By using a range of doses we have demonstrated a clear dose-response relationship for effects on both ApoA-I and HDL. These and other data are being used to develop an optimized dosage schedule for the planned clinical trials.
